Pace® Life Sciences Acquires Meridian BioGroup, Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets
Retrieved on:
Thursday, August 18, 2022
Aurora, FDA, Leonard Green & Partners, CEO, GLOBE, CDMO, Technology company, Haemophilus influenzae biogroup aegyptius, LLC, Compliance, Government, PR, Engineering, Acquisition, List of life sciences, Partnership, GMP, Biotechnology, Education, Communities and Justice Directorates, Quality control, Science, CTM, Partner, CMC, Fine chemical, Risk management, Audit, Meridian
Meridian specializes in bringing industry experts from regulatory affairs, quality, validation, and related backgrounds to meet its clients' needs in FDA-regulated environments.
Key Points:
- Meridian specializes in bringing industry experts from regulatory affairs, quality, validation, and related backgrounds to meet its clients' needs in FDA-regulated environments.
- Expertise gained through the Meridian acquisition allows Pace to extend the following capabilities to its clients:
Regulatory guidance and strategy supporting applications and submissions. - "The addition of the Meridian BioGroup team brings new dimensions to the range of services we provide to our clients," notes Greg Kupp, President of Pace Life Sciences.
- Meridian BioGroup LLC, is a Maryland-based validation, regulatory, and compliance contract service provider to the biotechnology and pharmaceutical communities.